A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Sponsor: ONO Pharmaceutical Co., Ltd.
Email for more information: Heme-NCIResearch@nortonhealthcare.org